Introduction
The development of proton pump inhibitors (PPIs) and their introduction in the late 1980s enabled significant improvement in the management of various acidrelated upper gastrointestinal disorders. Because of their efficiency, minimal side effects and general safety for long-term treatment, today they are the most common prescribed drugs in the treatment of acid-peptic diseases. A meta-analysis of 43 studies on gastroesophageal reflux disease (GERD), including 7,635 patients, demonstrated a more complete and twice as fast esophagitis healing and heartburn relief with PPIs versus histamine receptor antagonists (H 2 RAs) [1] .
However, in the last 10 years many articles regarding the unmet needs of acid suppression have been published indicating that currently available PPIs have notable limitations and are still far from the ideal antisecretory compound. The unmet needs relate to the lack of complete control of acid secretion with oral PPIs administration in the management of patients with gastroesophageal symptoms, nonvariceal upper gastrointestinal bleeding, nonsteroidal anti-inflammatory drugs (NSAIDs) and gastrointestinal tract mucosa injury, and Helicobacter pylori infection [2] [3] [4] [5] .
The question is whether the current PPIs still have hidden potential or unmet clinical needs that need to be ad-dressed with newer agents capable of achieving rapid and long-lasting acid suppression [6] .
Differences in PPI Pharmacokinetics
Differences in PPI pharmacokinetics, bioavailability, elimination half-life and metabolism have been observed and could be the answer for the differences in clinical outcomes [7] . PPI products currently available on the market (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) all contain a basic structural framework, 2-pyridylmethylsulfinylbenzimidazole pharmacophore, varying only in the specific side ring substitution. Tenatoprazole, a new PPI, has an imidazopyridine ring.
A PPI pKa of about 4.0 enables their accumulation only in the acidic secretory canaliculus of the stimulated parietal cell, where they are converted into thiophilic intermediates that bind to cysteine sulfhydryl groups on the luminal aspect of the proton pump to form covalent disulfide bonds. This covalent inhibition of the enzyme by the thiophilic sulfenamide results in a specific and long-lasting impairment of gastric acid secretion. The antisecretory effect of the drugs reflects their short plasma half-life (ranging from 1 to 1.5 h), the number of active pumps during that time, and the recovery of pumps following biosynthesis and reversal of inhibition [8] . Tenatoprazole, a new PPI that has a 5-to 7-fold longer elimination half-life than other current PPIs, could be potentially more useful for the treatment of GERD and NAB [4, 9] . One of the latest comparisons of pharmacodynamic and pharmacokinetic profiles of tenatoprazole and esomeprazole has shown significantly greater and more prolonged dose-dependent 24-hour and nocturnal acid suppression with S-tenatoprazole-Na than esomeprazole. S-tenatoprazole-Na may provide greater clinical efficacy compared with current PPIs for patients with ineffective once-daily therapy [10] .
PPI Formulation
PPIs are often referred to as prodrugs, although they do not require enzymatic activation. They are acid-labile, weak bases formulated as delayed-release enteric-coated preparations. An enteric coating protects PPIs from premature acid degradation in the stomach so that absorption can occur in the proximal small intestine. Because of that, there is a delay in absorption and onset of their antisecretory effect [11] . The lansoprazole fast disintegrating tablet, a so-called 'patient-friendly' and more convenient formulation of lansoprazole which can be taken with or without water, was the first PPI to be made available as an orally disintegrating tablet [12] . Unfortunately, no significant differences in symptom relief between the lansoprazole orally disintegrating tablet and esomeprazole were reported in patients with nonerosive reflux disease (NERD) [13] . A few years ago, immediaterelease omeprazole was introduced. It consists of pure, nonenteric-coated omeprazole powder along with sodium bicarbonate, which acts as a buffer against gastric acid degradation. The absence of an enteric coating facilitates rapid absorption. Studies have shown that immediate-release omeprazole, when compared to delayedrelease omeprazole, has a higher mean peak plasma concentration (C max 1,019 vs. 544 ng/ml) and a significantly shorter mean time to reach significantly shorter t max (25 vs . 127 min) [14] . In the management of nocturnal acid breakthrough (NAB), repeated once-daily (bedtime) dosing with immediate-release omeprazole produced significantly better results than repeated oncedaily (pre-dinner) or twice-daily dosing with delayedrelease pantoprazole. Twice-daily dosing (pre-breakfast and bedtime) with immediate-release omeprazole 20 and 40 mg achieved the best nighttime control of gastric acidity [15] .
Dose
There are differences in PPI bioavailability after a single and repeated dose. Early complete heartburn relief with PPIs for the entire day occurs in only 30% of patients after their first PPI dose and in 9% of patients after placebo. Although PPIs might provide benefit from the first day of therapy, most patients will not have symptom relief with 1 or 2 days of PPI therapy [16] . The first published comparative pharmacodynamic trial comparing standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole has shown that esomeprazole at the standard dose of 40 mg once daily provided more effective control of gastric acid at steady state than standard doses of other PPIs in patients with GERD symptoms [17] . The bioavailability of rabeprazole on day 1 is greater than with other PPIs, and this may translate into faster onset of symptom relief for patients with GERD. On the other hand, the bioavailability of esomeprazole increases 3-fold at day 5, and it has been shown that on day 5, esomeprazole provided a significantly more effective control of gastric acid than other PPIs. The exact clinical significance of these observations remains to be determined [18] . Differences in hepatic metabolism of PPIs due to cytochrome P450 2C19 genetic polymorphisms may influence clinical outcomes. In H. pylori eradication, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole and lansoprazole but not with rabeprazole. The esophagitis healing rate was lower in extensive metabolizers with lansoprazole but not with rabeprazole [7] .
Nutritional Intake and Food Timing
There is sufficient evidence to support the relationship between being obese/overweight and GERD, expressed as specific symptoms and endoscopic features. Furthermore, available evidence suggests that controlled weight loss is able to induce a significant improvement in GERD symptoms and/or in GERD clinical-endoscopic manifestations. It is a common belief that some foods may induce or worsen GERD symptoms. In daily clinical practice, this belief leads to advising patients to avoid the suspect foods. Since GERD symptoms are most commonly reported postprandial, the role of diet components in inducing symptoms has been suggested. However, different and conflicting results exist in the literature for identifying the most 'refluxogenic' foods. Clinical studies have shown a decrease in lower esophageal sphincter pressure and an increase in esophageal acid exposure in response to the ingestion of food rich in fats, chocolate and carminatives. Also, studies demonstrated that fried foods, spicy foods and alcohol are the most common precipitating factors of heartburn [19] . According to the study of ElSerag et al. [20] , there is a positive association between high fat intake and GERD symptoms as well as erosive esophagitis, while a high-fiber diet seemed to reduce reflux symptoms. The effects of fat on GERD symptoms and erosive esophagitis were dependent on BMI since this was statistically significant only in overweight individuals. While some authors have suggested that alcohol is an independent risk factor for GERD-related symptoms, others have not found such a relationship. A similar observation was seen for ingestion of coffee. While intraesophageal infusion of coffee in patients with acid sensitivity may induce heartburn, two large epidemiological studies have found no association between coffee drinking and GERD [21, 22] .
Effectiveness of a PPI is also dependent on food timing and food intake. As gastric acid secretion is maximally stimulated by food ingestion, maximal PPI efficacy should be achieved when they are taken before a meal. Hatlebakk's study [23] has shown an advantage in daytime intragastric pH control when a morning dose of omeprazole or lansoprazole were taken before breakfast compared with no breakfast. Therefore, intake of medication in relation to meals may be especially important to optimize their effect and avoid therapeutic failure. PPIs are most often prescribed for intake in the morning and in most individuals, once-daily dosing is sufficient to produce the desired level of acid inhibition, and a second dose, which is occasionally necessary, should be administered before the evening meal [2] .
What Do We Know about Unmet Needs?
Gastroesophageal Reflux Disease GERD is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms, with or without mucosal damage, and/or complications [24] . A systematic review of the epidemiology of GERD has demonstrated 10-20% prevalence, defined by at least weekly heartburn and/or acid regurgitation, in the Western world and less than 5% in Asia. The incidence in the Western world is approximately 5 per 1,000 person-years [25] . Although the PPIs are highly effective for the majority of patients with erosive esophagitis and considered the mainstay treatment for GERD, significant therapeutic challenges still exist. Surveys among primary care physicians indicate a number of areas of controversy and confusion related to the management of GERD. It was found that most primary care physicians prescribe PPIs for GERD without prior authorization and without first using an H 2 RA, and many of them give an H 2 RA with once-daily PPI treatment for patients with nocturnal heartburn. The appropriate advice regarding the importance of PPI use and food intake was less than 64% among patients [26] . The conclusion of a recently published review by Yuan and Hunt [27] was that a substantial number of patients fail to respond adequately to once-or even twice-daily PPI and that there is no standard definition of PPI failure in GERD as well as a universally accepted definition for treatment success.
The prevalence of PPI failure differs from patients with NERD and those with erosive esophagitis. PPIs provide a more modest therapeutic gain in patients with NERD as compared to those with erosive esophagitis. Total response rates at 4 weeks were significantly higher for patients with erosive esophagitis compared with NERD (56 vs. 37%) [28] . Studies in the different phenotypic presentations of GERD suggest that the overall prevalence of PPI failure is approximately 30% [29] . Meta-analysis of symptomatic GERD patients found that in about twothirds of patients, reflux symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% patients still suffer symptoms 3 days later [30] .
Nonerosive Reflux Disease NERD is the most common form of GERD. In a primary care setting, up to 70% of patients with typical symptoms of GERD have NERD. The closest entity to NERD that is examined by available epidemiologic studies is defined by the presence of GERD symptoms in the absence of esophageal erosions or Barrett's esophagus [31, 32] . NERD is often characterized with troublesome symptoms that affect the quality of life (QoL) similar to that reported by patients with erosive esophagitis. GERD patients with NERD are relatively refractory to the pharmacodynamic effects of PPIs on the postprandial integrated gastric acidity [33] , suggesting that their symptoms may be generated by different mechanisms than acid as in erosive esophagitis.
The proportion of NERD patients responding to a standard dose of PPIs is approximately 20-30% lower than what has been documented in patients with erosive esophagitis [29] [30] [31] . Progression to erosive GERD occurs in about 5% of NERD cases per year, despite standard therapy. Factors that consistently and independently influence this progression are smoking and the lack of a continuous PPI therapy during the follow-up period [34] .
Recently, biopsies established that subjects with heartburn and PPI-responsive NERD, like those with erosive esophagitis, have lesions within the esophageal epithelium known as dilated intercellular space, suggesting that dilated intercellular space might be involved in the development of persistent symptoms [35, 36] . Dexlansoprazole MR, a novel, modified-release formulation of dexlansoprazole, which incorporates dual delayed-release technology designed to prolong the serum concentrationtime profile, and thus provides extended acid suppression, has been recently assessed in NERD patients [37] . In a 4-week, double-blind, placebo-controlled study with 947 NERD patients, dexlansoprazole 30 mg/day for 4 weeks was shown to be superior to placebo in providing 24-hour heartburn-free days and nights (54.9 vs. 17.5% and 80.8 vs. 51.7%, respectively) [38] .
Erosive Esophagitis
Erosive esophagitis accounts for about 20-30% of patients with GERD, demonstrating 6-15% of PPI (oncedaily) treatment failure. Patients with more severe grades of erosive esophagitis have demonstrated a higher PPI failure rate than those with less severe disease [29] . Nonresponse of erosive esophagitis increases with severity of erosive esophagitis grading. The nonhealed rate for Los Angeles grade C and grade D erosive esophagitis on standard dose PPI suggests that approximately 40% of moderate (C) and 51% severe (D) erosive esophagitis were unhealed after 4 weeks and 18% of C and 27% of D at 8 weeks [39] .
Barrett's Esophagus
The prevalence of Barrett's esophagus is 6-12% of all patients who present for endoscopy with GERD-related symptoms, and 0.25-3.9% in unselected cases undergoing upper endoscopy [40] . Barrett's esophagus is considered to follow a progression from intestinal metaplasia to low-grade dysplasia to high-grade dysplasia and finally to esophageal adenocarcinoma in a subset of patients. Conservative management, involving symptom control and periodic endoscopic surveillance to exclude progressive disease, is recommended for patients with Barrett's esophagus without evidence of dysplasia or cancer. Lifestyle modifications can be helpful to increase esophageal acid clearance and decrease the incidence of reflux events [41] .
Atypical Symptoms GERD can be presented with atypical or extraesophageal symptoms, including asthma, unexplained chronic cough, laryngitis, oropharyngitis, nocturnal wheeze, chronic sore throat, dental erosions, and noncardiac chest pain. An empiric trial using PPIs is still the recommended initial approach in those suspected of having reflux as the cause for extraesophageal symptoms such as asthma, chronic cough or laryngitis, although recent randomized placebo-controlled studies have been disappointing in showing any benefit of acid-suppressive therapy [42] [43] [44] [45] [46] .
Nocturnal Acid Breakthrough NAB has been arbitrarily defined as the presence of gastric pH ! 4 for at least 1 h during the night -in patients on PPI therapy. This is a physiological phenomenon that has been observed in 75% of all individuals (GERD patients as well as healthy subjects) taking PPI twice a day [45] . A recent US survey of GERD patients taking PPIs clearly emphasized that over 80% of the patients reported night symptoms during the previous 30 days and 23.4% described symptoms as severe or very severe [46] . In total, 22% of responders were on twice-daily PPI and 42% supplemented prescribed PPIs by OTC PPIs, H 2 RAs, or antacids. Among patients on twice-daily PPI, 39.1% increased the dose due to poor symptom control at night [47] . Increased nighttime acidity leads to more severe GERD symptoms and could be associated with obstruc- tive sleep apnea [48] . Due to the short plasma half-life (1-2 h), delayed-release PPIs do not have an effect on acid suppression 5 h after the evening dose because there is no drug available to inhibit acid pumps synthesized during the nighttime hours, so intragastric pH may remain ! 4 for up to a third of the night [49] . Therefore, acid secretion after midnight is not controlled even with the most aggressive acid-suppressive therapy. A therapeutic approach that included the addition of H 2 RA at bedtime was introduced and quickly adopted. In summary, the presence of NAB in patients treated with a PPI is a physiological phenomenon that has yet to demonstrate an association with clinical parameters, such as symptoms or erosive esophagitis.
Rebound Acid Hypersecretion
Rebound is defined as an increase in gastric acid secretion above pre-treatment levels following discontinuation of antisecretory therapy. Rebound is clinically important because it seems that it contributes to the recurrence of GERD [50] . There are four mechanisms to explain rebound: upregulation of H 2 receptors, hypergastrinemia-stimulating histamine release by enterochromaffin-like cells, increase of parietal cell mass and upregulation of H + ,K + -ATPase activity [51] . Increased gastric acid secretion is well described after stopping the long-term use of H 2 RA [52, 53] , but its occurrence after the prolonged use of PPIs is controversial. It seems that there is no strong evidence for a clinically relevant increased acid output after PPI therapy is stopped [51] [52] [53] . Three uncontrolled trials nevertheless suggested an increase in acid secretory capacity in H. pylori-negative subjects after 8 weeks of treatment [54, 55] . In this situation, rebound hypersecretion, after attempting to stop the PPI, could result in GERD symptoms worsening and therefore resulting in prolongation of PPI use [52] . Perhaps the advice should be to never abruptly stop PPI therapy but to always step down to half strength and then to intermittent therapy if full symptom control is obtained. Whether on-demand therapy may also lead to rebound is unknown, but deserves to be evaluated [2] .
Quality of Life
Heartburn and acid regurgitation are the cardinal symptoms of GERD [56] . It is well known that the severity and frequency of these symptoms are associated with impaired QoL [57, 58] . Generic measurements have shown that GERD patients even have a lower QoL than patients with chronic ischemic heart disease [59] .
Today, PPIs are the most commonly prescribed drugs among GERD patients and play an important role in their QoL. The German prospective cohort study (ProGERD) with over 6,000 GERD patients determined that the QoL of individuals with reflux disease, in terms of both physical and psychosocial aspects of well-being, was significantly lower than that of the general population. Problems with eating and drinking, vitality and pain were defined as the most significant to impair the QoL. However, it was shown that this can easily be relieved or even eliminated within a short period of time (2 weeks) by treatment with esomeprazole, irrespective of whether the patient is suffering from NERD, erosive GERD or Barrett's esophagus [58] . Three years later the results of the first study that involved endoscopy in the general population suggest that the presence or absence of esophagitis does not appear to predict QoL impairment [59] . Recently, one study demonstrated that the QoL associated with the reflux esophagitis and NERD subtypes may be more related to psychological factors (anxiety and depression) than to symptom severity [60] .
Beyond Acid Suppression: Management of Failure
The logical step forward would be the next generation of drugs which suppress gastric acidity. A number of new drugs are currently being investigated. Potassium-competitive acid blockers (P-CABs) are potassium-competitive inhibitors of the ATPase [5] . Considering the main differences in the mechanism of action between P-CABs and PPIs, a clinically relevant fact is that P-CABs have a full effect after the first dose. Potassium-competitive antagonists and gastrin (CCK2) receptor antagonists reached clinical testing, but did not fulfill all the required clinical expectations. Dual approach, using PPIs in combination with transient lower esophageal sphincter relaxation (TLESR)-targeted agents, would reduce the time that patients need to achieve heartburn control and minimize a possible ceiling effect of PPI therapy [61] . Since PPIs have no effect on TLESR, new add-on medication therapies will be of great interest for pharmaceutical companies in the future.
Type B ␥ -aminobutyric agonists (GABA B ) are new medications which are currently undergoing clinical trials to establish their potential to reduce TLESR and reflux episodes, increase basal lower esophageal sphincter pressure and reduce swallowing. Limitations are small human phase 1 and 2 trails, and significant side effects, particularly those affecting the liver and central nervous sys-tem. Discovery of analogues with an improved side effect profile is warranted.
The metabotropic glutamate receptor antagonists have similar mechanism of action as GABA B agonists. Their research is currently in the phase of animal studies, except for one human proof-of-concept study [62] .
Endoscopic antireflux procedures were introduced with great enthusiasm at the beginning of this century, but after all a recent AGA Institute medical position statement recommended that 'current data suggest that there are no definite indications for endoscopic therapy for GERD at this time' [63] .
Conclusion
PPIs are a group of drugs that reduce the secretion of gastric acid and are highly successful for treating patients suffering from acid-related diseases. Unfortunately, there are still a significant number of patients that have persistent dyspeptic symptoms and a decreased QoL despite the use of PPIs. The unmet needs of PPIs relate to the lack of complete control of acid secretion with oral PPI administration in the management of patients with gastroesophageal symptoms, nonvariceal upper gastrointestinal bleeding, NSAID gastrointestinal injury and H. pylori . To increase the QoL of these patients and avoid multiple medical consultations and unnecessary investigations, we have to go one step forward and use combined therapy or look towards new treatments beyond acid suppression. Beside acid suppression, there are different potential targets in the pathophysiological mechanisms of GERD and acid-related diseases where we can act in order to accomplish the support for those patients. The role of such new medications and endoscopic procedures remains to be proven before placing patients on an add-on therapy to PPIs.
